GlassScriptPhysician profile
Rakesh V Alva
NPI 1093868929
$9,028.95
in general payments reported to CMS, 2019-2025
40 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $399 · 2021: $883 · 2022: $1,616 · 2023: $2,604 · 2024: $1,049 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,724 · Travel and Lodging: $1,146 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.44 |
| Travel and Lodging | $1,146.44 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,762.99 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,668.42 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $1,274.37 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.22 | 2019-2024 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $403.25 | 2019-2025 | |
| Mylan Specialty L.P. | $351.69 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $332.65 | 2020-2025 | Tyvaso, Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $325.94 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $256.75 | 2019-2025 | Uptravi, Opsynvi |
| Insmed, INC. | $228.18 | 2019-2025 | Brinsupri, Arikayce |
| Novartis Pharmaceuticals Corporation | $210.02 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.41 | 2021-2025 | Glassia |
| Merck Sharp & Dohme LLC | $194.31 | 2019-2025 | Zerbaxa |
| Philips North America LLC | $151.18 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Amgen INC. | $118.88 | 2022-2023 | Tezspire |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Alva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.